Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.

Wang T, Ueda Y, Zhang Z, Yin Z, Matiskella J, Pearce BC, Yang Z, Zheng M, Parker DD, Yamanaka GA, Gong YF, Ho HT, Colonno RJ, Langley DR, Lin PF, Meanwell NA, Kadow JF.

J Med Chem. 2018 Jul 26;61(14):6308-6327. doi: 10.1021/acs.jmedchem.8b00759. Epub 2018 Jul 13.

PMID:
29920093
2.

The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.

Scola PM, Sun LQ, Wang AX, Chen J, Sin N, Venables BL, Sit SY, Chen Y, Cocuzza A, Bilder DM, D'Andrea SV, Zheng B, Hewawasam P, Tu Y, Friborg J, Falk P, Hernandez D, Levine S, Chen C, Yu F, Sheaffer AK, Zhai G, Barry D, Knipe JO, Han YH, Schartman R, Donoso M, Mosure K, Sinz MW, Zvyaga T, Good AC, Rajamani R, Kish K, Tredup J, Klei HE, Gao Q, Mueller L, Colonno RJ, Grasela DM, Adams SP, Loy J, Levesque PC, Sun H, Shi H, Sun L, Warner W, Li D, Zhu J, Meanwell NA, McPhee F.

J Med Chem. 2014 Mar 13;57(5):1730-52. doi: 10.1021/jm500297k. Epub 2014 Mar 5.

PMID:
24564672
3.

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

Scola PM, Wang AX, Good AC, Sun LQ, Combrink KD, Campbell JA, Chen J, Tu Y, Sin N, Venables BL, Sit SY, Chen Y, Cocuzza A, Bilder DM, D'Andrea S, Zheng B, Hewawasam P, Ding M, Thuring J, Li J, Hernandez D, Yu F, Falk P, Zhai G, Sheaffer AK, Chen C, Lee MS, Barry D, Knipe JO, Li W, Han YH, Jenkins S, Gesenberg C, Gao Q, Sinz MW, Santone KS, Zvyaga T, Rajamani R, Klei HE, Colonno RJ, Grasela DM, Hughes E, Chien C, Adams S, Levesque PC, Li D, Zhu J, Meanwell NA, McPhee F.

J Med Chem. 2014 Mar 13;57(5):1708-29. doi: 10.1021/jm401840s. Epub 2014 Feb 20.

PMID:
24555570
4.

Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.

Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR 2nd, Colonno RJ, Gao M, Meanwell NA, Hamann LG.

J Med Chem. 2014 Mar 13;57(5):2013-32. doi: 10.1021/jm401836p. Epub 2014 Feb 12.

PMID:
24521299
5.

Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.

Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.

J Med Chem. 2014 Mar 13;57(5):1855-79. doi: 10.1021/jm4016894. Epub 2014 Jan 7.

PMID:
24397558
6.

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248).

Regueiro-Ren A, Xue QM, Swidorski JJ, Gong YF, Mathew M, Parker DD, Yang Z, Eggers B, D'Arienzo C, Sun Y, Malinowski J, Gao Q, Wu D, Langley DR, Colonno RJ, Chien C, Grasela DM, Zheng M, Lin PF, Meanwell NA, Kadow JF.

J Med Chem. 2013 Feb 28;56(4):1656-69. doi: 10.1021/jm3016377. Epub 2013 Feb 7.

PMID:
23360431
7.

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).

McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, Levine S, Chaniewski S, Yu F, Barry D, Chen C, Lee MS, Mosure K, Sun LQ, Sinz M, Meanwell NA, Colonno RJ, Knipe J, Scola P.

Antimicrob Agents Chemother. 2012 Oct;56(10):5387-96. doi: 10.1128/AAC.01186-12. Epub 2012 Aug 6.

8.

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043).

Kadow JF, Ueda Y, Meanwell NA, Connolly TP, Wang T, Chen CP, Yeung KS, Zhu J, Bender JA, Yang Z, Parker D, Lin PF, Colonno RJ, Mathew M, Morgan D, Zheng M, Chien C, Grasela D.

J Med Chem. 2012 Mar 8;55(5):2048-56. doi: 10.1021/jm201218m. Epub 2012 Feb 22.

PMID:
22356441
9.

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR 2nd, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG.

Nature. 2010 May 6;465(7294):96-100. doi: 10.1038/nature08960. Epub 2010 Apr 21.

PMID:
20410884
10.

Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.

Walsh AW, Langley DR, Colonno RJ, Tenney DJ.

PLoS One. 2010 Feb 12;5(2):e9195. doi: 10.1371/journal.pone.0009195.

11.

Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties.

Yang Z, Zadjura LM, Marino AM, D'Arienzo CJ, Malinowski J, Gesenberg C, Lin PF, Colonno RJ, Wang T, Kadow JF, Meanwell NA, Hansel SB.

J Pharm Sci. 2010 Apr;99(4):2135-52. doi: 10.1002/jps.21948.

PMID:
19780144
12.

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.

Wang T, Yin Z, Zhang Z, Bender JA, Yang Z, Johnson G, Yang Z, Zadjura LM, D'Arienzo CJ, DiGiugno Parker D, Gesenberg C, Yamanaka GA, Gong YF, Ho HT, Fang H, Zhou N, McAuliffe BV, Eggers BJ, Fan L, Nowicka-Sans B, Dicker IB, Gao Q, Colonno RJ, Lin PF, Meanwell NA, Kadow JF.

J Med Chem. 2009 Dec 10;52(23):7778-87. doi: 10.1021/jm900843g.

PMID:
19769332
13.

Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates.

Fang J, Wichroski MJ, Levine SM, Baldick CJ, Mazzucco CE, Walsh AW, Kienzle BK, Rose RE, Pokornowski KA, Colonno RJ, Tenney DJ.

Antimicrob Agents Chemother. 2009 Jul;53(7):2762-72. doi: 10.1128/AAC.00130-09. Epub 2009 May 11.

14.

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.

Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ.

Hepatology. 2009 May;49(5):1503-14. doi: 10.1002/hep.22841.

PMID:
19280622
15.

Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns.

Meanwell NA, Wallace OB, Fang H, Wang H, Deshpande M, Wang T, Yin Z, Zhang Z, Pearce BC, James J, Yeung KS, Qiu Z, Kim Wright JJ, Yang Z, Zadjura L, Tweedie DL, Yeola S, Zhao F, Ranadive S, Robinson BA, Gong YF, Wang HG, Spicer TP, Blair WS, Shi PY, Colonno RJ, Lin PF.

Bioorg Med Chem Lett. 2009 Apr 1;19(7):1977-81. doi: 10.1016/j.bmcl.2009.02.040. Epub 2009 Feb 13. Erratum in: Bioorg Med Chem Lett. 2010 Feb 15;20(4):1460. Spicer, Timothy P [added].

PMID:
19251416
16.

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance.

Baldick CJ, Tenney DJ, Mazzucco CE, Eggers BJ, Rose RE, Pokornowski KA, Yu CF, Colonno RJ.

Hepatology. 2008 May;47(5):1473-82. doi: 10.1002/hep.22211.

PMID:
18435459
17.

Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.

Baldick CJ, Eggers BJ, Fang J, Levine SM, Pokornowski KA, Rose RE, Yu CF, Tenney DJ, Colonno RJ.

J Hepatol. 2008 Jun;48(6):895-902. doi: 10.1016/j.jhep.2007.12.024. Epub 2008 Feb 21.

PMID:
18362040
18.

Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition.

Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ.

Antimicrob Agents Chemother. 2008 Feb;52(2):598-605. Epub 2007 Dec 3.

19.

Inhibition of hepatitis B virus polymerase by entecavir.

Langley DR, Walsh AW, Baldick CJ, Eggers BJ, Rose RE, Levine SM, Kapur AJ, Colonno RJ, Tenney DJ.

J Virol. 2007 Apr;81(8):3992-4001. Epub 2007 Jan 31.

20.

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.

Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ.

Antimicrob Agents Chemother. 2007 Mar;51(3):902-11. Epub 2006 Dec 18.

21.

Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability.

Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.

Bioorg Med Chem Lett. 2007 Feb 15;17(4):895-901. Epub 2006 Dec 1. Erratum in: Bioorg Med Chem Lett. 2007 Apr 15;17(8):2385.

PMID:
17169560
22.

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.

Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ.

Hepatology. 2006 Dec;44(6):1656-65.

PMID:
17133475
24.

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.

Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ, Springer MS, Moore JP.

Nature. 2005 Nov 3;438(7064):99-102. Epub 2005 Oct 30.

PMID:
16258536
25.

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.

Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Bacon BR, Poynard T, Joshi S, Klesczewski KS, Thiry A, Rose RE, Colonno RJ, Hindes RG; BEHoLD Study Group.

Gastroenterology. 2005 Oct;129(4):1198-209.

PMID:
16230074
26.

Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.

Yanchunas J Jr, Langley DR, Tao L, Rose RE, Friborg J, Colonno RJ, Doyle ML.

Antimicrob Agents Chemother. 2005 Sep;49(9):3825-32.

27.

Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.

Foster WK, Miller DS, Scougall CA, Kotlarski I, Colonno RJ, Jilbert AR.

J Virol. 2005 May;79(9):5819-32.

28.

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ.

Antimicrob Agents Chemother. 2004 Sep;48(9):3498-507.

29.

Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.

Wang T, Zhang Z, Wallace OB, Deshpande M, Fang H, Yang Z, Zadjura LM, Tweedie DL, Huang S, Zhao F, Ranadive S, Robinson BS, Gong YF, Ricarrdi K, Spicer TP, Deminie C, Rose R, Wang HG, Blair WS, Shi PY, Lin PF, Colonno RJ, Meanwell NA.

J Med Chem. 2003 Sep 25;46(20):4236-9.

PMID:
13678401
30.

Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.

Guo Q, Ho HT, Dicker I, Fan L, Zhou N, Friborg J, Wang T, McAuliffe BV, Wang HG, Rose RE, Fang H, Scarnati HT, Langley DR, Meanwell NA, Abraham R, Colonno RJ, Lin PF.

J Virol. 2003 Oct;77(19):10528-36.

31.

Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus.

Julander JG, Colonno RJ, Sidwell RW, Morrey JD.

Antiviral Res. 2003 Aug;59(3):155-61.

PMID:
12927305
32.

Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.

Foster WK, Miller DS, Marion PL, Colonno RJ, Kotlarski I, Jilbert AR.

Antimicrob Agents Chemother. 2003 Aug;47(8):2624-35.

34.

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.

Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ.

Antimicrob Agents Chemother. 2002 Aug;46(8):2525-32.

35.

Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.

Marion PL, Salazar FH, Winters MA, Colonno RJ.

Antimicrob Agents Chemother. 2002 Jan;46(1):82-8.

36.

Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

Colonno RJ, Genovesi EV, Medina I, Lamb L, Durham SK, Huang ML, Corey L, Littlejohn M, Locarnini S, Tennant BC, Rose B, Clark JM.

J Infect Dis. 2001 Nov 15;184(10):1236-45. Epub 2001 Oct 29.

PMID:
11679911
37.

Antiviral efficacy of lobucavir (BMS-180194), a cyclobutyl-guanosine nucleoside analogue, in the woodchuck (Marmota monax) model of chronic hepatitis B virus (HBV) infection.

Genovesi EV, Lamb L, Medina I, Taylor D, Seifer M, Innaimo S, Colonno RJ, Clark JM.

Antiviral Res. 2000 Dec;48(3):197-203.

PMID:
11164506
38.

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.

Gong YF, Robinson BS, Rose RE, Deminie C, Spicer TP, Stock D, Colonno RJ, Lin PF.

Antimicrob Agents Chemother. 2000 Sep;44(9):2319-26.

39.

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.

Robinson BS, Riccardi KA, Gong YF, Guo Q, Stock DA, Blair WS, Terry BJ, Deminie CA, Djang F, Colonno RJ, Lin PF.

Antimicrob Agents Chemother. 2000 Aug;44(8):2093-9.

40.

Stavudine resistance: an update on susceptibility following prolonged therapy.

Lin PF, González CJ, Griffith B, Friedland G, Calvez V, Ferchal F, Schinazi RF, Shepp DH, Ashraf AB, Wainberg MA, Soriano V, Mellors JW, Colonno RJ.

Antivir Ther. 1999;4(1):21-8.

PMID:
10682125
41.

De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus.

Luo G, Hamatake RK, Mathis DM, Racela J, Rigat KL, Lemm J, Colonno RJ.

J Virol. 2000 Jan;74(2):851-63.

42.

pH-dependent changes in photoaffinity labeling patterns of the H1 influenza virus hemagglutinin by using an inhibitor of viral fusion.

Cianci C, Yu KL, Dischino DD, Harte W, Deshpande M, Luo G, Colonno RJ, Meanwell NA, Krystal M.

J Virol. 1999 Mar;73(3):1785-94.

43.

Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus.

Yamanaka G, Wilson T, Innaimo S, Bisacchi GS, Egli P, Rinehart JK, Zahler R, Colonno RJ.

Antimicrob Agents Chemother. 1999 Jan;43(1):190-3.

44.

Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection.

Genovesi EV, Lamb L, Medina I, Taylor D, Seifer M, Innaimo S, Colonno RJ, Standring DN, Clark JM.

Antimicrob Agents Chemother. 1998 Dec;42(12):3209-17. Erratum in: Antimicrob Agents Chemother 1999 Mar;43(3):726.

45.

In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.

Seifer M, Hamatake RK, Colonno RJ, Standring DN.

Antimicrob Agents Chemother. 1998 Dec;42(12):3200-8.

46.

Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy.

Deminie CA, Bechtold CM, Riccardi K, Rose RE, Samanta H, Lin PF, Colonno RJ.

AIDS. 1998 Jan 1;12(1):110-2. No abstract available.

PMID:
9456262
47.

Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase.

Tenney DJ, Yamanaka G, Voss SM, Cianci CW, Tuomari AV, Sheaffer AK, Alam M, Colonno RJ.

Antimicrob Agents Chemother. 1997 Dec;41(12):2680-5.

48.

Differential effect of modified capped RNA substrates on influenza virus transcription.

Cianci C, Colonno RJ, Krystal M.

Virus Res. 1997 Jul;50(1):65-75.

PMID:
9255936
49.

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus.

Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ.

Antimicrob Agents Chemother. 1997 Jul;41(7):1444-8.

50.

Separate functional domains of the herpes simplex virus type 1 protease: evidence for cleavage inside capsids.

Robertson BJ, McCann PJ 3rd, Matusick-Kumar L, Newcomb WW, Brown JC, Colonno RJ, Gao M.

J Virol. 1996 Jul;70(7):4317-28.

Supplemental Content

Loading ...
Support Center